ER positive

P=N/A, N=305, Completed, Thomas Jefferson University | Active, not recruiting --> Completed

P=N/A, N=2000, Recruiting, National and Kapodistrian University of Athens

P3, N=1156, Suspended, Alliance for Clinical Trials in Oncology | Recruiting --> Suspended

P1/2, N=24, Not yet recruiting, University of Chicago

Here, we evaluated targeting candidates from this signature KMT5B/C and IKBKE using inhibitors A-196 and IKBKEi respectively, alongside anti-estrogen (fulvestrant) and a TGFβ blocking antibody (NIS793), both individually and in combination with αPD-L1, within this rat model. Comprehensive tumor profiling through polychromatic flow cytometry and single-cell RNA sequencing revealed that A-196 induced a luminal-to-basal shift in tumor epithelial cells, enhancing antigen presentation, whereas epithelial-to-mesenchymal transition was linked to fulvestrant resistance. Our findings underscore the value of the rat mammary tumor model for preclinical studies in ER-positive breast cancer and advocate for the further validation and potential clinical development of KMT5B/C inhibitors to enhance the efficacy and broaden the applicability of ICI therapy in cancer patients.

S.J.L. received funding from an NHMRC Project Grant ID: 1125433.

Because of this, early risk assessment and tailored imaging are crucial for timely diagnosis. This review defines high-risk factors for breast cancer, and the management of these individuals during pregnancy and lactation.

P=N/A, N=70, Not yet recruiting, Assiut University

Using different DTI parameters can enhance the accuracy of breast cancer characterization reducing unnecessary biopsies, provide valuable data to correlate with tumor grade, differentiate luminal from non-luminal lesions, thus providing insights into the aggressiveness of the tumor.

Our comprehensive analysis of cell-cell communication networks among epithelial cells, fibroblasts, macrophages, and lymphocytes across BC subtypes focuses on ligand-receptor interactions. This study revealed that certain molecules within these networks exhibit significant prognostic value and therapeutic promise.

Over the past century, women in the US are attaining menarche earlier, more likely to have their first birth after age 30 and having fewer births. Parsing the extent to which changes in reproductive factors are contributing to the rising incidence of estrogen receptor positive breast cancer, especially in premenopausal women, is necessary to devise long-lasting and sustainable preventive strategies.

We propose that future trials involving women with premenopausal ER-positive disease must prioritize biology over age in defining eligibility, incorporate OFS as a SOC in the control arm and expand biomarker-driven approaches to refine both treatment escalation and de-escalation. A genomically and immunologically informed strategy is essential to improve the outcomes in this under-represented population.